European Imaging Agent Market size is estimated to reach USD 3.3 billion by 2028, according to a latest forecast report by Graphical Research.
Increasing number of cardiovascular disorders and cancer cases across the Europe region is anticipated to boost the market demand. For instance, according to the European Society of Cardiology (ESC), in Europe, cardiovascular diseases (CVD) are still the leading cause of death and a major cause of morbidity. Also stated that, in 2019, over 6 million new cases of CVD in the EU were recorded. Similarly, as per the data published by European Commission, in 2020, colorectal cancer accounted for 12.7% of all new cancer diagnoses and 12.4% of all deaths due to cancer. As a result, it is the second most common cancer after breast cancer and the second leading cause of death from cancer after lung cancer. The burden of cardiovascular and cancer disease has increased across European region as a result of rising alcohol and tobacco usage. Tobacco usage accounts for almost 22% of all cancer deaths.
Imaging agents are used to determine cancer stages (how far it has progressed) and whether the cancer is in, around, or near important organs and blood arteries. In addition, several cardiac MRI studies use intravenous gadolinium-based contrast agents (GBCAs) to increase the visibility of the blood flow and heart muscle. Furthermore, the use of microbubbles, iodine, and gadolinium imaging agents is becoming more common in cancer imaging techniques such as lung, thyroid, and breast cancer imaging. As a result, the rising popularity of imaging agents for pre-diagnosis of breast cancer and colorectal cancer will propel the market size.
The microbubble contrast media segment exceeded USD 299 million revenue in 2021, attributed to increasing demand for microbubbles in echocardiography imaging procedures as well as rising adoption of microbubbles contrast agents in various ultrasound-based molecular diagnostic procedures. Moreover, microbubble contrast media are small injectable gas bubbles, and it is used to detect the biomarker condition of imaging inflammation and visualize tumor vasculature and endothelium, among other things.
The neurology segment accounted for USD 257.6 million revenue in 2021, due to the increasing use of MRI contrast media in the diagnosis of neurological disorders as it provides better images of neural structures than CT. Gadolinium-based contrast agents are used for visualizing neoplastic lesions, inflammatory, and demyelinated. Moreover, the most commonly used macrocyclic gadolinium-based contrast agents in the diagnosis of neurological disorders are Gadavist, Dotarem, and Prohance. They are approved for intravenous use in adults and pediatric patients aged 2 and up to visualize lesions with abnormal vascularity in the spine, brain and associated tissues.
The computed tomography segment held over 25.6% market share in 2021. Contrast agents for CT scan aid in the formation of high 3D structural images. CT procedures rely on iodinated and barium-based contrast media. When imaging agents like iodine and barium are injected into the body, they block X-rays and prevent them from passing through. As a result, images of blood vessels, organs, and other bodily tissues containing iodinated and barium-based contrast agents change. The widespread usage of CT for a variety of disorders is projected to drive the market expansion.
Browse detailed statistical insights from the report, “Europe Imaging Agents Market Forecast 2028 By Modality (X-Ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound), By Product Type (Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media, Barium-based Contrast Media), By Application (Oncology, Cardiology, Gastrointestinal, Neurology), By End-use (Hospitals, Ambulatory Surgical Centers, Diagnostic & Imaging Centers), Research Report, Country Outlook (Germany, France, UK, Italy, Spain, The Netherlands, Denmark, Russia, Poland, Sweden), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @
Furthermore, a CT scan is a common procedure used in the diagnosis of COVID-19. The chest CT for pulmonary embolism is becoming more popular because it is effective at detecting both alternate diagnoses and COVID-19 complications. Furthermore, CT may reveal signs of viral pneumonia, assisting in clinical diagnosis.
The diagnostic & imaging center segment dominated around 27% market share in 2021, owing to the presence of trained professionals, improved imaging agents, and advanced equipment to perform a variety of screening tests. Additionally, diagnostic & imaging centers utilize innovative X-ray systems and blood tests to evaluate a person's condition and provide cost-effective and high-quality treatment.
The Germany imaging agent market will witness 4.4% CAGR during the forecast period, on account of easy availability of advanced technologies and the presence of well-developed healthcare facilities as well as the high demand for diagnostic procedures in this country. Furthermore, several market participants focused on developing innovative imaging agents for improved patient management and undertaking promotional and marketing efforts to raise public awareness about the availability of superior imaging agents.
The imaging agent in European market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2017 to 2028, for the following segments:
Europe Market, By Product Type
- Iodinated Contrast Media
- Gadolinium-based Contrast Media
- Microbubble Contrast Media
- Barium-based Contrast Media
Europe Market, By Application
Europe Market, By Modality
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
Europe Market, By End-use
- Ambulatory surgical centers
- Diagnostic & imaging centers
The above information has been provided for the following countries:
- The Netherlands